Showing 1 – 5 of 5
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 8, 2024

    Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

    Steven E.听Nissen,聽MD; Kathy聽Wolski,聽MPH; Gerald F.听Watts,聽MD, DSc; Michael J.听Koren,聽MD; Henry聽Fok,聽MBBS, PhD; Stephen J.听Nicholls,聽MBBS, PhD; David A.听Rider,聽PhD; Leslie聽Cho,聽MD; Steven聽Romano,聽MD; Carrie聽Melgaard,聽MS; Curtis聽Rambaran,聽MBBS, MD
    Abstract Full Text
    JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504

    This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.

  • JAMA Cardiology Original Investigation
    April 7, 2024

    Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial

    Daniel聽Gaudet,聽MD, PhD; Denes聽Pall,聽MD, PhD; Gerald F.听Watts,聽DSc, PhD, MD; Stephen J.听Nicholls,聽MBBS, PhD; Robert S.听Rosenson,聽MD; Karen聽Modesto,聽MD; Javier聽San Martin,聽MD; Jennifer聽Hellawell,聽MD; Christie M.听Ballantyne,聽MD
    Abstract Full Text
    online first
    JAMA Cardiol. 2024; 10.1001/jamacardio.2024.0959

    This randomized clinical trial assesses the safety and effectiveness of plozasiran, an investigational APOC3-targeted drug, in the reduction of serum triglyceride level in patients with severe hypertriglyceridemia.

  • JAMA Comment & Response
    November 28, 2023

    USPSTF Recommendation on Screening for Lipid Disorders in Children and Adolescents

    Raul D.听Santos,聽MD, PhD; Peter聽Libby,聽MD; Gerald F.听Watts,聽DSc, PhD, DM
    Abstract Full Text
    JAMA. 2023; 330(20):2022-2023. 10.1001/jama.2023.20449
  • JAMA Pediatrics Original Investigation
    May 1, 2023

    Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands

    Zanfina聽Ademi,聽PhD; Richard聽Norman,聽PhD; Jing聽Pang,聽PhD; Eric聽Sijbrands,聽PhD; Gerald F.听Watts,聽DSc; Barbara A.听Hutten,聽PhD; Albert聽Wiegman,聽PhD
    Abstract Full Text
    free access has multimedia
    JAMA Pediatr. 2023; 177(6):625-632. 10.1001/jamapediatrics.2023.0763

    This study investigates cost-effectiveness and the return on investment of a nationwide case-finding and preventive treatment program starting with identification of familial hypercholesterolemia in children and treatment.

  • JAMA Preliminary Communication
    April 3, 2022

    Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

    Steven E.听Nissen,聽MD; Kathy聽Wolski,聽MPH; Craig聽Balog,聽BS; Daniel I.听Swerdlow,聽MD, PhD; Alison C.听Scrimgeour,聽MSc; Curtis聽Rambaran,聽MD; Rosamund J.听Wilson,聽PhD; Malcom聽Boyce,聽MD; Kausik K.听Ray,聽MD; Leslie聽Cho,聽MD; Gerald F.听Watts,聽MD, PhD; Michael聽Koren,聽MD; Traci聽Turner,聽MD; Erik S.听Stroes,聽MD, PhD; Carrie聽Melgaard,聽MS; Giles V.听Campion,聽MD, PhD
    Abstract Full Text
    free access has multimedia
    JAMA. 2022; 327(17):1679-1687. 10.1001/jama.2022.5050

    This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.